CWEB vs. MDP, RX, HLS, TGOD, NINE, WMD, SUGR, VIR, ZOM, and VRX
Should you be buying Charlotte's Web stock or one of its competitors? The main competitors of Charlotte's Web include Medexus Pharmaceuticals (MDP), BioSyent (RX), HLS Therapeutics (HLS), Green Organic Dutchman (TGOD), Delta 9 Cannabis (NINE), WeedMD (WMD), SugarBud Craft Growers (SUGR), Viridium Pacific Group (VIR), Zomedica Pharmaceuticals Corp. (ZOM.V) (ZOM), and Valeant Pharmaceuticals International (VRX). These companies are all part of the "drug manufacturers - specialty & generic" industry.
Medexus Pharmaceuticals (CVE:MDP) and Charlotte's Web (TSE:CWEB) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, valuation, community ranking, institutional ownership, earnings, profitability, risk, analyst recommendations and dividends.
Medexus Pharmaceuticals has a net margin of 0.00% compared to Medexus Pharmaceuticals' net margin of -52.37%. Charlotte's Web's return on equity of 0.00% beat Medexus Pharmaceuticals' return on equity.
Medexus Pharmaceuticals received 27 more outperform votes than Charlotte's Web when rated by MarketBeat users. Likewise, 62.79% of users gave Medexus Pharmaceuticals an outperform vote while only 0.00% of users gave Charlotte's Web an outperform vote.
Charlotte's Web has lower revenue, but higher earnings than Medexus Pharmaceuticals. Medexus Pharmaceuticals is trading at a lower price-to-earnings ratio than Charlotte's Web, indicating that it is currently the more affordable of the two stocks.
In the previous week, Charlotte's Web had 2 more articles in the media than Medexus Pharmaceuticals. MarketBeat recorded 2 mentions for Charlotte's Web and 0 mentions for Medexus Pharmaceuticals. Charlotte's Web's average media sentiment score of 0.00 beat Medexus Pharmaceuticals' score of -0.06 indicating that Medexus Pharmaceuticals is being referred to more favorably in the media.
Medexus Pharmaceuticals currently has a consensus price target of C$3.18, indicating a potential downside of 59.03%. Given Charlotte's Web's higher possible upside, analysts plainly believe Medexus Pharmaceuticals is more favorable than Charlotte's Web.
3.7% of Charlotte's Web shares are owned by institutional investors. 11.2% of Charlotte's Web shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Summary
Medexus Pharmaceuticals beats Charlotte's Web on 10 of the 16 factors compared between the two stocks.
Get Charlotte's Web News Delivered to You Automatically
Sign up to receive the latest news and ratings for CWEB and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Charlotte's Web Competitors List
Related Companies and Tools
